PPC
CSTL icon

Park Place Capital’s Castle Biosciences CSTL Stock Holding History

Park Place Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-53
Closed -$895 – 909
2023
Q3 		$895 Hold
53
– – ﹤0.01% 981
2023
Q2 		$727 Hold
53
– – ﹤0.01% 998
2023
Q1 		$1.2K Hold
53
– – ﹤0.01% 982
2022
Q4 		$1K Buy
+53
New +$1.23K ﹤0.01% 989

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Park Place Capital's CSTL Position: Q4 2023 in Review

Park Place Capital sold out of Castle Biosciences (CSTL) in Q4 2023, closing a stake of 53 shares — an estimated $895 sold.

Park Place Capital first reported a position in CSTL in Q4 2022 and held it in 4 quarters. The position peaked at $1.2K in Q1 2023. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2023.

  • Park Place Capital reported no remaining Castle Biosciences position as of Q4 2023 after selling out during the quarter.
  • Park Place Capital sold 53 Castle Biosciences shares in Q4 2023, an estimated $895.
  • Park Place Capital first reported a position in Castle Biosciences in Q4 2022 and held it in 4 quarters.
  • Park Place Capital's Castle Biosciences position peaked at $1.2K in Q1 2023.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2023.

Based on Park Place Capital's 13F filing for Q4 2023, filed 24 Jan 2024.